Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (go-raise)

Désirée Van der Heijde, Jürgen Braun, Atulya (Atul) Deodhar, Robert D. Inman, Stephen Xu, Michael E. Mack, Benjamin Hsu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective. To compare the abilities of three enthesitis indices to detect improvement in entheseal tenderness with the TNF antagonist golimumab in AS.Methods. Adult patients with active AS were randomly assigned to receive s.c. injections of placebo or golimumab (50 or 100 mg) every 4 weeks. Patients with inadequate week 16 responses were switched (blinded) from placebo to golimumab 50 mg or from golimumab 50 mg to 100 mg. At week 24, all patients still receiving placebo crossed over to golimumab 50 mg. Enthesitis data through week 52 are reported herein. Enthesitis was measured by a trained, independent assessor who recorded the presence or absence of tenderness in 27 entheses, which allowed simultaneous determination of three different indices [12-point Berlin Index, 17-point University of California, San Francisco (UCSF) Index and 13-point Maastricht AS Enthesitis Score (MASES)].Results. Three hundred and fifty-six AS patients were randomized to placebo (n=78), golimumab 50 mg (n=138) or golimumab 100 mg (n=140); 355 had enthesitis data available for analysis. Using the UCSF Index, significant improvement from baseline vs placebo was observed for golimumab 100 mg at weeks 14 and 24. Using the MASES, significant improvement for golimumab 100 mg vs placebo at week 14 and a trend toward improvement at week 24 were observed. Using the Berlin Index, significant improvement for golimumab 100 mg vs placebo at week 14 was observed. Effect size determinations for changes to weeks 14, 24 and 52, respectively, in the Berlin (-0.27, -0.34, -0.42), UCSF (-0.44, -0.61, _0.55) and MASES (-0.30, -0.55, -0.39) indices suggested small to moderate effect sizes.Conclusion. In patients with active AS, the UCSF Index appeared most sensitive in detecting the effect of golimumab 100 mg vs placebo on enthesitis.

Original languageEnglish (US)
Article numberkes251
Pages (from-to)321-325
Number of pages5
JournalRheumatology (United Kingdom)
Volume52
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Ankylosing Spondylitis
Randomized Controlled Trials
Placebos
San Francisco
Berlin
golimumab

Keywords

  • Ankylosing spondylitis
  • Anti-TNF
  • Assessment tool
  • Enthesitis

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (go-raise). / Van der Heijde, Désirée; Braun, Jürgen; Deodhar, Atulya (Atul); Inman, Robert D.; Xu, Stephen; Mack, Michael E.; Hsu, Benjamin.

In: Rheumatology (United Kingdom), Vol. 52, No. 2, kes251, 02.2013, p. 321-325.

Research output: Contribution to journalArticle

Van der Heijde, Désirée ; Braun, Jürgen ; Deodhar, Atulya (Atul) ; Inman, Robert D. ; Xu, Stephen ; Mack, Michael E. ; Hsu, Benjamin. / Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (go-raise). In: Rheumatology (United Kingdom). 2013 ; Vol. 52, No. 2. pp. 321-325.
@article{1fc5e9b83d6d45f5b8d7a2ccc2209408,
title = "Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (go-raise)",
abstract = "Objective. To compare the abilities of three enthesitis indices to detect improvement in entheseal tenderness with the TNF antagonist golimumab in AS.Methods. Adult patients with active AS were randomly assigned to receive s.c. injections of placebo or golimumab (50 or 100 mg) every 4 weeks. Patients with inadequate week 16 responses were switched (blinded) from placebo to golimumab 50 mg or from golimumab 50 mg to 100 mg. At week 24, all patients still receiving placebo crossed over to golimumab 50 mg. Enthesitis data through week 52 are reported herein. Enthesitis was measured by a trained, independent assessor who recorded the presence or absence of tenderness in 27 entheses, which allowed simultaneous determination of three different indices [12-point Berlin Index, 17-point University of California, San Francisco (UCSF) Index and 13-point Maastricht AS Enthesitis Score (MASES)].Results. Three hundred and fifty-six AS patients were randomized to placebo (n=78), golimumab 50 mg (n=138) or golimumab 100 mg (n=140); 355 had enthesitis data available for analysis. Using the UCSF Index, significant improvement from baseline vs placebo was observed for golimumab 100 mg at weeks 14 and 24. Using the MASES, significant improvement for golimumab 100 mg vs placebo at week 14 and a trend toward improvement at week 24 were observed. Using the Berlin Index, significant improvement for golimumab 100 mg vs placebo at week 14 was observed. Effect size determinations for changes to weeks 14, 24 and 52, respectively, in the Berlin (-0.27, -0.34, -0.42), UCSF (-0.44, -0.61, _0.55) and MASES (-0.30, -0.55, -0.39) indices suggested small to moderate effect sizes.Conclusion. In patients with active AS, the UCSF Index appeared most sensitive in detecting the effect of golimumab 100 mg vs placebo on enthesitis.",
keywords = "Ankylosing spondylitis, Anti-TNF, Assessment tool, Enthesitis",
author = "{Van der Heijde}, D{\'e}sir{\'e}e and J{\"u}rgen Braun and Deodhar, {Atulya (Atul)} and Inman, {Robert D.} and Stephen Xu and Mack, {Michael E.} and Benjamin Hsu",
year = "2013",
month = "2",
doi = "10.1093/rheumatology/kes251",
language = "English (US)",
volume = "52",
pages = "321--325",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (go-raise)

AU - Van der Heijde, Désirée

AU - Braun, Jürgen

AU - Deodhar, Atulya (Atul)

AU - Inman, Robert D.

AU - Xu, Stephen

AU - Mack, Michael E.

AU - Hsu, Benjamin

PY - 2013/2

Y1 - 2013/2

N2 - Objective. To compare the abilities of three enthesitis indices to detect improvement in entheseal tenderness with the TNF antagonist golimumab in AS.Methods. Adult patients with active AS were randomly assigned to receive s.c. injections of placebo or golimumab (50 or 100 mg) every 4 weeks. Patients with inadequate week 16 responses were switched (blinded) from placebo to golimumab 50 mg or from golimumab 50 mg to 100 mg. At week 24, all patients still receiving placebo crossed over to golimumab 50 mg. Enthesitis data through week 52 are reported herein. Enthesitis was measured by a trained, independent assessor who recorded the presence or absence of tenderness in 27 entheses, which allowed simultaneous determination of three different indices [12-point Berlin Index, 17-point University of California, San Francisco (UCSF) Index and 13-point Maastricht AS Enthesitis Score (MASES)].Results. Three hundred and fifty-six AS patients were randomized to placebo (n=78), golimumab 50 mg (n=138) or golimumab 100 mg (n=140); 355 had enthesitis data available for analysis. Using the UCSF Index, significant improvement from baseline vs placebo was observed for golimumab 100 mg at weeks 14 and 24. Using the MASES, significant improvement for golimumab 100 mg vs placebo at week 14 and a trend toward improvement at week 24 were observed. Using the Berlin Index, significant improvement for golimumab 100 mg vs placebo at week 14 was observed. Effect size determinations for changes to weeks 14, 24 and 52, respectively, in the Berlin (-0.27, -0.34, -0.42), UCSF (-0.44, -0.61, _0.55) and MASES (-0.30, -0.55, -0.39) indices suggested small to moderate effect sizes.Conclusion. In patients with active AS, the UCSF Index appeared most sensitive in detecting the effect of golimumab 100 mg vs placebo on enthesitis.

AB - Objective. To compare the abilities of three enthesitis indices to detect improvement in entheseal tenderness with the TNF antagonist golimumab in AS.Methods. Adult patients with active AS were randomly assigned to receive s.c. injections of placebo or golimumab (50 or 100 mg) every 4 weeks. Patients with inadequate week 16 responses were switched (blinded) from placebo to golimumab 50 mg or from golimumab 50 mg to 100 mg. At week 24, all patients still receiving placebo crossed over to golimumab 50 mg. Enthesitis data through week 52 are reported herein. Enthesitis was measured by a trained, independent assessor who recorded the presence or absence of tenderness in 27 entheses, which allowed simultaneous determination of three different indices [12-point Berlin Index, 17-point University of California, San Francisco (UCSF) Index and 13-point Maastricht AS Enthesitis Score (MASES)].Results. Three hundred and fifty-six AS patients were randomized to placebo (n=78), golimumab 50 mg (n=138) or golimumab 100 mg (n=140); 355 had enthesitis data available for analysis. Using the UCSF Index, significant improvement from baseline vs placebo was observed for golimumab 100 mg at weeks 14 and 24. Using the MASES, significant improvement for golimumab 100 mg vs placebo at week 14 and a trend toward improvement at week 24 were observed. Using the Berlin Index, significant improvement for golimumab 100 mg vs placebo at week 14 was observed. Effect size determinations for changes to weeks 14, 24 and 52, respectively, in the Berlin (-0.27, -0.34, -0.42), UCSF (-0.44, -0.61, _0.55) and MASES (-0.30, -0.55, -0.39) indices suggested small to moderate effect sizes.Conclusion. In patients with active AS, the UCSF Index appeared most sensitive in detecting the effect of golimumab 100 mg vs placebo on enthesitis.

KW - Ankylosing spondylitis

KW - Anti-TNF

KW - Assessment tool

KW - Enthesitis

UR - http://www.scopus.com/inward/record.url?scp=84873874141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873874141&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kes251

DO - 10.1093/rheumatology/kes251

M3 - Article

VL - 52

SP - 321

EP - 325

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 2

M1 - kes251

ER -